Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 7/20 | 0.46 |
| ▸ | CNR2 | P34972 | 9/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767088 | 0.93 | KDM4E (0.49) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL6769130 | 0.91 | PDE4B (0.46) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL5769456 | 0.88 | CNR2 (0.52) | CNR1CNR2 | |
| SCHEMBL5769074 | 0.85 | CNR2 (0.42) | CNR1CNR2 | |
| SCHEMBL5794921 | 0.85 | PDE4B (0.43) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL5766978 | 0.85 | CNR2 (0.41) | CNR1CNR2 | |
| SCHEMBL6770731 | 0.84 | PDE4B (0.48) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL6768892 | 0.84 | CNR1 (0.43) | KDM4EMAPTKMT2ACNR1 | |
| SCHEMBL5769821 | 0.83 | CNR1 (0.50) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL5768717 | 0.80 | CNR2 (0.54) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | claimed |
| EP-1622876-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004099157-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM4E 3327/4885MEN1 4525/4885MAPT 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.